Mirati Therapeutics, Inc. Profile Avatar - Palmy Investing

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
MRTX/Financials
Supply · Problems · Premarket · Compliance

Supply Analysis

Supply Analysis